Skip to main content
Top
Published in: Rheumatology International 5/2019

Open Access 01-05-2019 | Juvenile Rheumatoid Arthritis | Review

Rheumatology in Poland

Authors: Maria Maślińska, Tomasz Dobrzyński, Brygida Kwiatkowska

Published in: Rheumatology International | Issue 5/2019

Login to get access

Abstract

The aim of this article is to present the current state of rheumatology in Poland, including the scientific and clinical activity and essential aspects of Polish rheumatic patients’ treatment. PubMed, Scopus and Web of Science databases were searched for main keywords: “rheumat*” and affiliation with Poland. Statistical data were obtained from the Central Statistical Office, the National Health Fund and the Polish Chamber of Physicians and Dentists, while the public information from the Polish Society for Rheumatology, the Ministry of Health and the Ministry of Science and Higher Education. Databases of the World Health Organization, the Organization for Economic Co-operation and Development and the European Statistical Office (Eurostat) were used. Most Polish rheumatologists work in large urban agglomerations in the Mazovian, Malopolskie and Silesian Voivodeships. The rheumatologic infrastructure includes 1713 working rheumatologists (> 30% exceeding the age of 60 years), 2301 hospital beds, 2279 outpatient clinics and 955 private practices. Poland’s state funding is relatively limited, this problem being addressed by health officials with special treatment programs for biological drugs. The Eurostat data indicate, that in Poland, like in the majority of EU Member States, there’s a tendency of specialist/general practitioner ratio rising. The number of scientific publications by Polish rheumatologists has steadily increased in recent years. Poland’s rheumatology has made an enormous progress at all levels of functioning in recent decades. The EULAR recommendations are mostly incorporated into the Polish health system, leaving still room for its further improvement in the fields of financing, therapy and education.
Literature
6.
go back to reference Batko B, Stajszczyk M, Świerkot J et al (2019) Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. Arch Med Sci 15(1):134–140CrossRefPubMed Batko B, Stajszczyk M, Świerkot J et al (2019) Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. Arch Med Sci 15(1):134–140CrossRefPubMed
7.
go back to reference Rudan I, Sidhu S, Papana A et al (2015) Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J Glob Health 5(1):010409CrossRefPubMedPubMedCentral Rudan I, Sidhu S, Papana A et al (2015) Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J Glob Health 5(1):010409CrossRefPubMedPubMedCentral
8.
go back to reference Andrianakos A, Trontzas P, Christoyannis F, for the ESORDIG study group, et al (2006) Prevalence and management of rheumatoid arthritis in the general population of Greece—the ESORDIG study, Rheumatology 45(12):1549–1554CrossRefPubMed Andrianakos A, Trontzas P, Christoyannis F, for the ESORDIG study group, et al (2006) Prevalence and management of rheumatoid arthritis in the general population of Greece—the ESORDIG study, Rheumatology 45(12):1549–1554CrossRefPubMed
9.
go back to reference Świerkot J, Batko B, Wiland P, Jędrzejewski M, Stajszczyk M (2018) Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice. Reumatologia 56(1):3–9CrossRefPubMedPubMedCentral Świerkot J, Batko B, Wiland P, Jędrzejewski M, Stajszczyk M (2018) Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice. Reumatologia 56(1):3–9CrossRefPubMedPubMedCentral
10.
go back to reference Kay J, Schoels MM, Dörner T et al (2018) Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 77:165–174CrossRefPubMed Kay J, Schoels MM, Dörner T et al (2018) Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 77:165–174CrossRefPubMed
12.
go back to reference Smolen JS, Landewé R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977CrossRef Smolen JS, Landewé R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977CrossRef
14.
go back to reference Foster HE, Minden K, Clemente D et al (2017) EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis 76:639–646CrossRefPubMed Foster HE, Minden K, Clemente D et al (2017) EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis 76:639–646CrossRefPubMed
15.
go back to reference Dincer U, Cakar E, Kiralp MZ, Dursun H (2008) Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27(4):457–462CrossRefPubMed Dincer U, Cakar E, Kiralp MZ, Dursun H (2008) Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27(4):457–462CrossRefPubMed
16.
17.
go back to reference Hatemi G, Christensen R, Bang D et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77:808–818PubMed Hatemi G, Christensen R, Bang D et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77:808–818PubMed
18.
go back to reference Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum 76(8):1327–1339CrossRef Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum 76(8):1327–1339CrossRef
19.
go back to reference Gasik R, Kamińska-Tchórzewska E (2013) Osteoporosis fracture of sacral bone treated with bone cement—sacroplasty. Reumatologia 51(4):304–307CrossRef Gasik R, Kamińska-Tchórzewska E (2013) Osteoporosis fracture of sacral bone treated with bone cement—sacroplasty. Reumatologia 51(4):304–307CrossRef
20.
go back to reference Zaidi HA, Montoure AJ, Dickman CA (2015) Surgical and clinical efficacy of sacroiliac joint fusion: a systematic review of the literature. J Neurosurg Spine 23:59–66CrossRefPubMed Zaidi HA, Montoure AJ, Dickman CA (2015) Surgical and clinical efficacy of sacroiliac joint fusion: a systematic review of the literature. J Neurosurg Spine 23:59–66CrossRefPubMed
22.
go back to reference Dobrzyński D, Boguszewska-Czubara A, Sugimori K (2018) Hydrogeochemical and biomedical insights into germanium potential of curative waters: a case study of health resorts in the Sudetes Mountains (Poland). Environ Geochem Health 40(4):1355–1375CrossRefPubMedPubMedCentral Dobrzyński D, Boguszewska-Czubara A, Sugimori K (2018) Hydrogeochemical and biomedical insights into germanium potential of curative waters: a case study of health resorts in the Sudetes Mountains (Poland). Environ Geochem Health 40(4):1355–1375CrossRefPubMedPubMedCentral
23.
go back to reference Brzozowski R (2007) Wspomnienie o profesorze Witoldzie Orłowskim. Postępy Nauk Med 2–3:99–104 Brzozowski R (2007) Wspomnienie o profesorze Witoldzie Orłowskim. Postępy Nauk Med 2–3:99–104
24.
go back to reference Maślińska M (2011) She started everything: tribute to Professor Eleonora Reicher on the 60th anniversary of the Institute of Rheumatology. Reumatologia 49(5):315–320 Maślińska M (2011) She started everything: tribute to Professor Eleonora Reicher on the 60th anniversary of the Institute of Rheumatology. Reumatologia 49(5):315–320
25.
go back to reference Sadowska-Wróblewska M (1973) Prof. Dr. med. Eleonora Reicher Reumatologia 11:201–203PubMed Sadowska-Wróblewska M (1973) Prof. Dr. med. Eleonora Reicher Reumatologia 11:201–203PubMed
28.
go back to reference Al Maini M, Adelowo F, Al Saleh J et al (2014) The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol 34(5):819–829CrossRefPubMedPubMedCentral Al Maini M, Adelowo F, Al Saleh J et al (2014) The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol 34(5):819–829CrossRefPubMedPubMedCentral
29.
go back to reference Gransalke K (2017) Publication analysis 2013–2017. Rheumatology Lab Times 1:32–34 Gransalke K (2017) Publication analysis 2013–2017. Rheumatology Lab Times 1:32–34
Metadata
Title
Rheumatology in Poland
Authors
Maria Maślińska
Tomasz Dobrzyński
Brygida Kwiatkowska
Publication date
01-05-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04287-8

Other articles of this Issue 5/2019

Rheumatology International 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine